Clinical Trial Update: PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update of PARP inhibitor as oral maintenance in low-risk ovarian cancer is underway, status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• PARP inhibitor

Snippet

Sponsor: Seoul National University Hospital | Conditions: Epithelial Ovarian Cancer, Ovarian Cancer | Phase 4 | Status: UNKNOWN